Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed plus irinotecan as second-line treatment for advanced colorectal cancer
ChiCTR1800016185Phase 4Recruiting
- Sponsor
- Nanjing Bayi Hospital
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raltitrexed and irinotecan in colorectal cancer (CRC), sponsored by Nanjing Bayi Hospital. Primary endpoint: Progression-free survival. Started Dec 2017; status: recruiting.
02
Drugs
raltitrexedirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800016185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016185.